Herpes zoster vaccine（recombinant，adjuvanted）
- Generic Name
- Herpes zoster vaccine（recombinant，adjuvanted）
- Indication
用于50岁及以上成人带状疱疹的预防。
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 120
- Registration Number
- NCT06162494
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls
Phase 4
Active, not recruiting
- Conditions
- RZV Vaccine (Shingrix ®)
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Calmy Alexandra
- Target Recruit Count
- 225
- Registration Number
- NCT05575830
- Locations
- 🇫🇷
CHU de Bordeaux - Hôpital Haut-Lévèque, Pessac, Gironde, France
🇫🇷SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin, Bordeaux, France
🇫🇷Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6138
- Registration Number
- NCT04869982
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath